Adaptimmune's Stock Trades Higher As TCR Therapy Shows Initial Durability In Soft Tissue Cancer Settings

Adaptimmune Therapeutics plc ADAP revealed initial data from its Phase 2 SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4).
Data will be presented at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.
According to the new data from the company's TCR therapy shrunk the tumors of 13 of the 33 evaluable second-line sarcoma patients.
The overall response rate was 39.3%, with 41.4% (12/29) for synovial sarcoma; 25.0% (1/4) for myxoid/ round cell liposarcoma (MRCLS).
The company said that the initial durability data is encouraging, and the median duration of response has not been reached.
On the safety front, afami-cel has been favorable, with mainly low-grade cytokine release syndrome and tolerable/reversible hematologic toxicities.
The company plans to file for approval in 2022.
Price Action: ADAP shares are up 8.6% at $5.32 during the premarket session on the last check Thursday.